Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis

Table 2 Direct pairwise comparisons and heterogeneity

Comparison	Pairwise OR (95% CI)	Number of events	Number of patients	Number of studies	Heterogeneity test
Comparison	Pairwise OR (95% CI)	Number of events	Number of patients	Number of studies	I ² (%)^a	p value^b
All-cause mortality
IV COL vs.
GLY + IV COL	1.13 (0.59–2.19)	59	160	2	0.0	0.63
IH COL + IV COL	0.80 (0.58–1.11)	285	642	7	18.2	0.29
RIF + IV COL	0.94 (0.57–1.56)	119	252	2	0.0	0.47
TIG	1.73 (1.08–2.78)	144	293	3	0.0	0.78
CAR + IV COL vs.
SUL + IV COL	1.59 (0.60–4.20)	43	77	2	43.2	0.18
Clinical cure
IV COL vs.
CAR + IV COL	0.81 (0.37–1.76)	199	248	2	0.0	0.46
IH COL + IV COL	1.60 (1.05–2.46)	363	695	7	38.0	0.14
TIG	0.91 (0.43–1.89)	59	125	2	0.0	0.83
CAR + IV COL vs.
SUL + IV COL	0.60 (0.17–2.11)	51	77	2	11.3	0.29
Microbiological eradication
IV COL vs.
IH COL + IV COL	1.28 (0.88–1.57)	242	465	5	0.0	0.73
RIF + IV COL	1.87 (1.13–3.10)	138	252	2	0.0	0.90
TIG	0.45 (0.18–1.11)	39	125	2	53.4	0.14
CAR + IV COL vs.
SUL + IV COL	1.36 (0.45–4.10)	52	77	2	0.0	0.95

Abbreviations: CAR carbapenem (imipenem or meropenem), CI confidence interval, COL colistin, FOS fosfomycin, GLY glycopeptide (vancomycin or teicoplanin), HD high dose, IH inhaled, IV intravenous, OR odds ratio, RIF rifampin, SUL sulbactam, TIG tigecycline, vs. versus
^aQuantified value of OR variation attributable to heterogeneity
^b p value from Q test based on chi-square statistic

ISSN: 1364-8535